Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Hung Do sold 50,194 shares of Amicus Therapeutics stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total value of $715,264.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up 2.38% during midday trading on Friday, reaching $13.77. The company’s stock had a trading volume of 885,178 shares. Amicus Therapeutics, Inc. has a 1-year low of $4.41 and a 1-year high of $16.60. The company’s 50-day moving average price is $14.35 and its 200 day moving average price is $11.26. The firm’s market capitalization is $2.27 billion.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. The company had revenue of $7.16 million during the quarter, compared to analyst estimates of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same quarter last year, the firm earned ($0.40) EPS. On average, equities research analysts forecast that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Amicus Therapeutics, Inc. (NASDAQ:FOLD) Insider Hung Do Sells 50,194 Shares” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/hung-do-sells-50194-shares-of-amicus-therapeutics-inc-fold-stock.html.
Several analysts recently issued reports on FOLD shares. JPMorgan Chase & Co. restated an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. BidaskClub downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Chardan Capital reaffirmed a “buy” rating and issued a $16.50 price target (down from $17.50) on shares of Amicus Therapeutics in a report on Wednesday, September 13th. Finally, Robert W. Baird upped their price target on Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, July 12th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Amicus Therapeutics currently has an average rating of “Buy” and an average price target of $17.81.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC lifted its holdings in shares of Amicus Therapeutics by 3.4% in the 2nd quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock worth $215,876,000 after purchasing an additional 705,153 shares during the last quarter. Redmile Group LLC lifted its holdings in shares of Amicus Therapeutics by 5.9% in the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock worth $121,282,000 after purchasing an additional 668,080 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Amicus Therapeutics by 5.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after purchasing an additional 430,486 shares during the last quarter. Palo Alto Investors LLC lifted its holdings in shares of Amicus Therapeutics by 0.7% in the 2nd quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock worth $79,964,000 after purchasing an additional 57,800 shares during the last quarter. Finally, Janus Capital Management LLC lifted its holdings in shares of Amicus Therapeutics by 3.6% in the 1st quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock worth $50,883,000 after purchasing an additional 244,906 shares during the last quarter.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.